Antibe Therapeutics Inc. (ATBPF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Devices industria. La empresa tiene su sede en Toronto, ON, Canada. El CEO actual es Daniel Marcel Legault.
ATBPF tiene fecha de IPO 2014-10-09, 11 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $11.43M.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
